gms | German Medical Science

6. Symposium Health Technology Assessment

Deutsche Agentur für HTA des DIMDI – DAHTA@DIMDI

03. bis 04.11.2005, Köln

Polymorphism screening

Meeting Abstract

Suche in Medline nach

  • author Claudia Wild - Unit for Health Technology Assessment, Institute of Technology Assessment, Austrian Academy of Sciences, Vienna, Austria

Deutsche Agentur für Health Technology Assessment des Deutschen Instituts für Medizinische Dokumentation und Information. 6. Symposium Health Technology Assessment. Köln, 03.-04.11.2005. Düsseldorf, Köln: German Medical Science; 2006. Doc05hta06

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter: http://www.egms.de/de/meetings/hta2005/05hta06.shtml

Veröffentlicht: 13. Februar 2006

© 2006 Wild.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielfältigt, verbreitet und öffentlich zugänglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Abstract

Pharmacogenetics focuses on the variation between individuals in their response to medicines. The expectations are that with applying pharmacogenetics, individualized treatment regimes will be safer and more efficacious, adverse reactions and effects of new medicines become predictable.

Pharmacogenetic knowledge is progressing fast, polymorphism tests are already carried out in individuals in either private institutions or in academic hospitals. The public demand started to grow for polymorphism test stimulated by commercially advertised tests: Before diffusing into the health care system - unevaluated and eventually with unintended effects - this early assessment on the socio-economic impact of individualized medicine aims at informing policy making by advising on regulatory issues and on priority setting.

Three fields of diseases are assessed at ITA:

  • polymorphism testing of healthy for genetic predisposition and accordingly early treatment,
  • polymorphism testing of patients for their metabolization status and accordingly individualized drug and doses choices and
  • genetic testing of tumour tissue and accordingly targeted treatment of selected patients

Notes

The complete lecture can be found on the website of DIMDI: http://www.dimdi.de/static/de/hta/symposien/2005/index.htm